BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $15.57.

A number of research firms recently issued reports on BCRX. JMP Securities reiterated a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective on the stock. Royal Bank of Canada restated an "outperform" rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, Evercore ISI raised their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its position in BioCryst Pharmaceuticals by 5.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company's stock valued at $14,349,000 after buying an additional 102,860 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock worth $2,274,000 after acquiring an additional 86,571 shares in the last quarter. FMR LLC raised its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company's stock valued at $15,112,000 after purchasing an additional 46,110 shares during the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at about $201,000. Finally, Captrust Financial Advisors boosted its holdings in BioCryst Pharmaceuticals by 19.4% during the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company's stock worth $124,000 after purchasing an additional 2,644 shares during the last quarter. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded up $0.41 during mid-day trading on Tuesday, hitting $6.82. The company's stock had a trading volume of 3,113,466 shares, compared to its average volume of 2,805,137. The company has a market cap of $1.43 billion, a PE ratio of -11.18 and a beta of 1.75. The company's fifty day simple moving average is $7.96 and its 200-day simple moving average is $7.74. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The business's quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.28 EPS. On average, equities analysts anticipate that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.